This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): paroxetine HCL, Seroxat [UK], Paxil CR, Aropax
Description: The efficacy of Paxil is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-hydroxy-tryptamine, 5-HT).
SkyePharma reformulated Paxil in a controlled release formulation using its Geomatrix oral technology, and will receive an undisclosed milestone payment when Paxil CR is launched, in addition to royalties on net sales.
GSK and Dianippon Sumitomo
In January 2012, GlaxoSmithKline and Dainippon Sumitimo announced that the companies have reached a basic agreement to co-promote Paxil controlled-release (CR) Tablets 12.5mg and Paxil CR Tablets 25mg (paroxetine hydrochloride hydrate) in Japan. In March 2012, the two companies signed a co-promotion agreement for Paxil CR Tablets. GSK will deal with distribution and sales.
In August 2012, GlaxoSmithKline reached agreement to divest the majority of its Classic Brands (25 non-promoted and genericised products) in Australia to Aspen for approximately GBP 172 million in cash. The divested brands include Valtrex, Lamictal, Timentin, Amoxil and Aropax. In December 2012, GlaxoSmithKline completed its divestment of its...See full deal structure in Biomedtracker
Partners: GlaxoSmithKline plc Aspen Pharmacare Holdings Limited
Pink Sheet Paxil CR FDA Reviewers
Pink Sheet Paxil CR Clinical Protocols
Pink Sheet Paxil CR Clinical Development
Additional information available to subscribers only: